X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DR. DATSONS LABS AJANTA PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 21.4 -10.9 - View Chart
P/BV x 5.0 0.2 3,096.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 AJANTA PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
DR. DATSONS LABS
Mar-14
AJANTA PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs1,818126 1,447.5%   
Low Rs1,10631 3,579.3%   
Sales per share (Unadj.) Rs239.5133.0 180.1%  
Earnings per share (Unadj.) Rs52.80.2 34,821.1%  
Cash flow per share (Unadj.) Rs59.56.6 900.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs230.0128.8 178.6%  
Shares outstanding (eoy) m88.7731.66 280.4%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x6.10.6 1,037.6%   
Avg P/E ratio x27.7516.1 5.4%  
P/CF ratio (eoy) x24.611.8 207.5%  
Price / Book Value ratio x6.40.6 1,046.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m129,7822,477 5,238.6%   
No. of employees `0006.8NA-   
Total wages/salary Rs m3,76556 6,722.7%   
Avg. sales/employee Rs Th3,128.4NM-  
Avg. wages/employee Rs Th554.0NM-  
Avg. net profit/employee Rs Th689.7NM-  
INCOME DATA
Net Sales Rs m21,2584,211 504.9%  
Other income Rs m24279 307.0%   
Total revenues Rs m21,4994,289 501.2%   
Gross profit Rs m6,584569 1,157.9%  
Depreciation Rs m596204 291.5%   
Interest Rs m4430 1.0%   
Profit before tax Rs m6,22613 49,019.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5396 25,231.1%   
Profit after tax Rs m4,6865 97,633.3%  
Gross profit margin %31.013.5 229.3%  
Effective tax rate %24.748.0 51.5%   
Net profit margin %22.00.1 19,338.3%  
BALANCE SHEET DATA
Current assets Rs m12,2366,852 178.6%   
Current liabilities Rs m3,4616,711 51.6%   
Net working cap to sales %41.33.3 1,232.8%  
Current ratio x3.51.0 346.3%  
Inventory Days Days60161 37.4%  
Debtors Days Days84318 26.5%  
Net fixed assets Rs m11,1403,673 303.3%   
Share capital Rs m177317 55.9%   
"Free" reserves Rs m20,2373,761 538.1%   
Net worth Rs m20,4144,078 500.6%   
Long term debt Rs m101,671 0.6%   
Total assets Rs m24,48612,633 193.8%  
Interest coverage x1,519.41.0 147,584.6%   
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x0.90.3 260.5%   
Return on assets %19.23.4 556.3%  
Return on equity %23.00.1 19,501.6%  
Return on capital %30.57.7 397.5%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m11,667964 1,210.3%   
Fx outflow Rs m1,616607 266.1%   
Net fx Rs m10,052357 2,816.4%   
CASH FLOW
From Operations Rs m2,8541,345 212.2%  
From Investments Rs m-2,604-2,256 115.5%  
From Financial Activity Rs m-2-1,200 0.2%  
Net Cashflow Rs m248-2,111 -11.8%  

Share Holding

Indian Promoters % 73.8 4.5 1,629.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.0 -  
FIIs % 7.6 1.4 563.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 94.1 18.1%  
Shareholders   20,968 20,807 100.8%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SUN PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  DR. REDDYS LAB  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 17.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, AJANTA PHARMA has posted a net profit of Rs 945 m (down 17.1% YoY). Sales on the other hand came in at Rs 5 bn (up 11.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 14, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - TORRENT PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS